Remove Drug Development Remove Leadership Remove Life Science Remove Pharmaceuticals
article thumbnail

Seamless Therapeutics Launches with $12.5M Seed Financing to Advance Transformative Gene Editing Platform Based on Programmable Precision Designer Recombinases

Digital Health Global

The seed round was co-led by Wellington Partners and Forbion and includes non-dilutive financing from BMBF GO-Bio, a prestigious German government initiative aimed at supporting the most innovative startups in the life sciences. Forbion invests in life sciences companies that are active in the (bio) pharmaceutical space.

article thumbnail

Where are HealthTech's soft landing M&A deals in today's market?

Lloyd Price

Traditional healthcare players: Hospitals, insurers, and pharmaceutical companies are increasingly acquiring healthtech startups to improve efficiency, patient engagement, and data-driven decision making. Visit [link] HealthTech Corporate Development - Buy Side, Sell Side, Growth & Strategy services for Founders, Owners and Investors.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Accenture Invests in QuantHealth to Accelerate Use of AI-Powered Clinical Trial Simulations to Drive Cost-Effective Drug Development

Healthcare IT Today

Accenture announced it has made a strategic investment, through Accenture Ventures , in QuantHealth , an AI-powered clinical trial design company that simulates clinical trials in the cloud, allowing pharmaceutical and biotech companies to more quickly and cost-effectively develop treatments for patients. Petra Jantzer, Ph.D.,

article thumbnail

Turbine Upsizes its Series A Round to €25.5 Million and Appoints Seasoned Independent Directors to its Board

Digital Health Global

These individuals have personally built leading technology platforms supercharging drug development globally. Their buy-in shows that our platform is differentiated and poised to unlock truly novel therapies for currently underserved patient populations through efficient, simulation-guided development. Jane Rhodes, Ph.D.,

BioTech 88